Coronavirus: Biocon & Biocon Biologics ensuring manufacturing of life-saving medicines

Biocon Ltd. and Biocon Biologics have activated business continuity plans across their functions to meet the needs of patients, partners, customers and other stakeholders who depend on its products.

As a global company, it has presence across India, UAE, Malaysia, Singapore, Europe, U.S. and are adjusting all operations to fully comply with regulations issued by respective national governments. 

In India, home to the largest part of the company’s workforce, the government announced a 21-day nationwide lockdown on Tuesday, March 24, 2020, but permitted “essential services” such as manufacturing of pharmaceuticals to continue. Biocon will continue to operate essential pharmaceutical manufacturing in full compliance with government requirements.

Chairperson Kiran Mazumdar-Shaw said, “As a globally recognized biopharmaceuticals company engaged in innovative science to develop new drugs and manufacturing life-saving therapies, we have a significant role to play in the global pharma ecosystem. At the same time, we also have a role to play in the national response to the COVID-19 threat. Indian Prime Minister Narendra Modi’s call for a 21-day nationwide lockdown is a good move to stop social transmission of the novel coronavirus. We are supporting local health officials and government leaders as they work to mitigate the disease. Now is not the time to step away from our duties but to step forward to play our part and serve the nation.”

Biocon and its subsidiary Biocon Biologics are fully supportive of the Indian government’s decision and are aligned with the authorities to address this national emergency. The company has created a task force to deal with this pandemic situation.

Since the company is involved in manufacturing of essential drugs, it has been assessing the impact of the lockdown by finding ways to continue with manufacturing operations of essential pharmaceuticals, biopharmaceuticals and APIs in order to meet commitments to patients, customers and partners.

While supply chain disruptions and impaired mobility due to lockdowns have a direct bearing on the operations, the company is working to minimise disruption to production schedules and supply of drugs to its customers and partners.

What's your take on this post ? Comment: